Richard B Lipton Selected Research

Apolipoproteins

11/2020	Education and the moderating roles of age, sex, ethnicity and apolipoprotein epsilon 4 on the risk of cognitive impairment.
1/2020	APOE ε4 and the Influence of Sex, Age, Vascular Risk Factors, and Ethnicity on Cognitive Decline.
1/2019	Determinants of cognitive performance and decline in 20 diverse ethno-regional groups: A COSMIC collaboration cohort study.
3/2017	Age-related cognitive decline and associations with sex, education and apolipoprotein E genotype across ethnocultural groups and geographic regions: a collaborative cohort study.
5/2016	Cholesteryl ester transfer protein genotype modifies the effect of apolipoprotein ε4 on memory decline in older adults.
1/2015	Correcting Bias Caused by Missing Data in the Estimate of the Effect of Apolipoprotein ε4 on Cognitive Decline.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richard B Lipton Research Topics

Disease

218	Migraine Disorders (Migraine) 04/2024 - 01/2002
108	Headache (Headaches) 01/2024 - 01/2002
60	Pain (Aches) 03/2024 - 01/2002
23	Alzheimer Disease (Alzheimer's Disease) 01/2024 - 05/2005
22	Cognitive Dysfunction 04/2024 - 02/2005
18	Nausea 01/2023 - 04/2010
15	Dementia (Dementias) 01/2024 - 02/2005
13	Headache Disorders (Headache Syndromes) 06/2021 - 07/2003
12	Epilepsy (Aura) 01/2022 - 04/2005
10	Prescription Drug Overuse 02/2024 - 10/2006
9	Hyperalgesia 12/2023 - 06/2009
8	Obesity 08/2017 - 10/2006
5	Hypertension (High Blood Pressure) 01/2023 - 07/2002
5	Hyperacusis (Phonophobia) 10/2022 - 04/2010
5	Photophobia (Light Sensitivity) 10/2022 - 04/2010
5	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 05/2004
5	Inflammation (Inflammations) 11/2018 - 01/2011
4	Disease Progression 01/2024 - 02/2009
4	Dizziness (Lightheadedness) 06/2022 - 01/2011
4	Migraine with Aura (Familial Hemiplegic Migraine) 01/2022 - 08/2005
4	Stroke (Strokes) 01/2022 - 02/2010
4	Parkinson Disease (Parkinson's Disease) 10/2017 - 07/2006
4	Primary Headache Disorders 04/2017 - 05/2005
4	Fatigue 11/2014 - 02/2007
3	Vascular Diseases (Vascular Disease) 04/2024 - 07/2012
3	Chronic Pain 12/2023 - 01/2009
3	Secondary Headache Disorders 01/2023 - 08/2013
3	Sleepiness 06/2022 - 04/2011
3	Tension-Type Headache (Tension Headache) 10/2017 - 06/2010
3	Insulin Resistance 01/2015 - 04/2006
2	Constipation 01/2023 - 01/2021
2	Dysgeusia (Parageusia) 01/2021 - 05/2018
2	Asthma (Bronchial Asthma) 01/2021 - 07/2002
2	Partial Epilepsies (Epilepsy, Partial) 11/2019 - 01/2018
2	Urinary Tract Infections (Urinary Tract Infection) 01/2019 - 11/2014

Drug/Important Bio-Agent (IBA)

37	Tryptamines (Triptans)IBA 02/2024 - 01/2002
25	Calcitonin Gene-Related Peptide Receptor AntagonistsIBA 04/2024 - 04/2011
24	Calcitonin Gene-Related PeptideIBA 03/2024 - 05/2007
24	Type A Botulinum Toxins (Botox)FDA Link 11/2023 - 06/2010
22	Opioid Analgesics (Opioids)IBA 02/2024 - 05/2004
18	Pain-FreeIBA 07/2022 - 11/2002
16	ubrogepantIBA 03/2024 - 08/2016
16	Biomarkers (Surrogate Marker)IBA 01/2024 - 11/2013
14	Monoclonal AntibodiesIBA 01/2024 - 01/2018
14	erenumabIBA 01/2024 - 01/2018
13	rimegepant sulfateIBA 04/2024 - 01/2019
12	Caffeine (No Doz)FDA LinkGeneric 12/2023 - 07/2002
11	eptinezumabIBA 01/2024 - 11/2014
11	Sumatriptan (Imigran)FDA LinkGeneric 01/2019 - 11/2002
9	atogepantIBA 03/2024 - 01/2021
9	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2023 - 09/2008
9	preemptIBA 12/2020 - 06/2010
8	fremanezumabIBA 01/2024 - 11/2015
8	Topiramate (Topamax)FDA LinkGeneric 11/2020 - 02/2007
7	Analgesics (Analgesic Drugs)IBA 02/2024 - 07/2002
7	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 02/2024 - 04/2005
6	TabletsIBA 04/2024 - 10/2012
6	Acetaminophen (Paracetamol)FDA LinkGeneric 02/2024 - 03/2006
6	galcanezumabIBA 01/2024 - 09/2018
6	Apolipoproteins E (ApoE)IBA 01/2023 - 01/2019
6	ApolipoproteinsIBA 11/2020 - 01/2015
6	BarbituratesIBA 06/2015 - 11/2008
5	Amyloid (Amyloid Fibrils)IBA 01/2023 - 01/2019
5	lasmiditanIBA 06/2022 - 12/2018
5	C-Reactive ProteinIBA 05/2022 - 01/2011
5	salicylhydroxamic acid (SHAM)IBA 01/2022 - 04/2010
5	SolutionsIBA 01/2021 - 11/2010
5	barbituric acid (barbiturate)IBA 01/2019 - 02/2009
4	Nasal SpraysIBA 01/2023 - 05/2018
4	Polymethyl Methacrylate (Sol)IBA 01/2023 - 01/2020
4	Indicators and Reagents (Reagents)IBA 01/2021 - 08/2017
4	Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)IBA 01/2020 - 01/2018
4	PowdersIBA 01/2019 - 11/2010
3	Hormones (Hormone)IBA 12/2023 - 07/2016
3	Amyloid beta-PeptidesIBA 11/2021 - 05/2005
3	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2017
3	Celecoxib (Celebrex)FDA Link 01/2021 - 01/2020
3	Naproxen (Naprosyn)FDA LinkGeneric 04/2019 - 07/2010
3	Nonprescription Drugs (Patent Medicines)IBA 10/2018 - 01/2005
3	Ibuprofen (Motrin)FDA LinkGeneric 10/2017 - 03/2006
3	Diclofenac (SR 38)FDA LinkGeneric 05/2017 - 02/2004
2	AntibodiesIBA 03/2024 - 07/2018
2	Oral ContraceptivesIBA 12/2023 - 10/2009
2	Prescription DrugsIBA 12/2022 - 10/2018
2	CytokinesIBA 05/2022 - 01/2018
2	Apolipoprotein E4IBA 01/2022 - 05/2016
2	CholesterolIBA 10/2020 - 01/2019
2	LipidsIBA 09/2019 - 01/2019
2	DFN-02IBA 01/2019 - 05/2018

Therapy/Procedure

69	Therapeutics 03/2024 - 01/2002
6	Ambulatory Care (Outpatient Care) 06/2021 - 01/2012
6	Autogenic Training 03/2021 - 12/2012
5	Aftercare (After-Treatment) 10/2022 - 04/2010
5	Contraindications 06/2022 - 09/2013
4	Injections 01/2024 - 06/2010
4	Drug Therapy (Chemotherapy) 03/2021 - 05/2009
3	Transcranial Magnetic Stimulation 01/2018 - 04/2010
2	Activities of Daily Living (ADL) 01/2022 - 10/2018
2	Vagus Nerve Stimulation 01/2022 - 08/2016
2	Psychology Biofeedback (Biofeedback) 10/2021 - 02/2011